Night-time compression with a Mobiderm® auto-adjustable arm-sleeve in addition to daytime compression was superior to daytime compression alone for maintenance therapy of upper limb lymphedema in breast cancer patients in a randomized controlled trial: LYMphoNIGHT study.
Clinical Snapshot
PICO Framework
| P — Population | Women with secondary upper limb breast cancer-related lymphedema (BCRL) who had completed intensive decongestive lymphedema therapy |
| I — Intervention | Night-time compression sleeve (MOBIDERM Autofit) plus daytime compression |
| C — Comparator | Daytime compression sleeve alone (no night compression) |
| O — Outcomes | Primary: change in arm excess volume at 3 months. Secondary: quality of life, sleep quality, skin thickness and suppleness, satisfaction, compliance, safety |
Bottom Line
This multicenter RCT demonstrates that adding night-time compression to standard daytime compression significantly improves lymphedema management in breast cancer survivors. The intervention group showed a 29% reduction in excess arm volume compared to a 10% increase in controls over 3 months, with substantially lower treatment failure rates (3.6% vs 23.1%). Additional benefits included improved quality of life, sleep quality, and skin parameters. While the study cannot be blinded due to the nature of compression therapy, the large effect size and comprehensive outcomes support the clinical utility of night-time compression. The intervention appears feasible for Australian practice, particularly for patients struggling with lymphedema maintenance despite standard daytime compression. Clinicians should consider this approach for patients with persistent or worsening BCRL during maintenance therapy, ensuring appropriate patient selection and education regarding compliance with night-time compression protocols.
Key Findings
P Value: p = 0.001
Effect Size: 29.2% decrease in MobA group vs 10.7% increase in Control group
Primary Outcome: Change in arm excess volume at 3 months
Nnt Or Sensitivity: Treatment failure rate: 3.6% (MobA) vs 23.1% (Control), suggesting NNT approximately 5
Confidence Interval: Not reported in abstract
Clinical Application
Requires patient education and compliance with night-time compression; availability of auto-adjustable compression devices Relevant to Australian lymphedema services; compression garments may be PBS-subsidized under certain circumstances; aligns with RACGP chronic disease management principles Women with established BCRL who have completed intensive decongestive therapy and require maintenance treatment
Abstract
PURPOSE: To assess the benefit of night-time compression in addition to daytime compression on arm excess volume after 3 months of maintenance treatment in patients with secondary upper limb breast cancer-related lymphedema (BCRL). METHODS: This multicenter, controlled, randomized study was carried out in six centers in France and Turkey. Women with upper limb BCRL who had undergone the intensive phase of decongestive lymphedema therapy (DLT) were randomized into two groups: the Control group wore a daytime compression sleeve without any night compression for 3 months and the MOBIDERM Autofit (MobA) group used a night-time compression sleeve in addition to the daytime compression. The primary outcome was the change in arm excess volume between day 0 (D0) and D90. The main secondary endpoints were: quality of life (QoL), sleep quality, skin thickness and suppleness, satisfaction, compliance, and safety. RESULTS: Fifty-six patients were recruited (mean (± SD) age: 61.4 ± 12.3 years). Between D0 and D90, the mean excess volume decreased by 29.2% in the MobA group and increased by 10.7% in the Control group (p = 0.001). Only 3.6% of patients in the MobA group presented with treatment failure vs. 23.1% in the Control group. At D90, patients in the MobA group had a significantly greater improvement in QoL (p < 0.05), sleep quality (p = 0.018), skin suppleness (p = 0.01) reduced skin thickness (p = 0.025) compared with the Control group. CONCLUSION: MOBIDERM Autofit used in addition to daytime compression for 3 months during the maintenance phase after DLT was superior to daytime compression alone for the reduction of arm excess volume. Registered on ClinicalTrials.gov (NCT04203069; 17/12/2019).
References
- 1.Borman, P., Mestre, S., Cakit, B. D., Giordana, P., Atar, B., Vernhet, E., Blaise, S., & Quéré, I. (2026). Night-time compression with a Mobiderm® auto-adjustable arm-sleeve in addition to daytime compression was superior to daytime compression alone for maintenance therapy of upper limb lymphedema in breast cancer patients in a randomized controlled trial: LYMphoNIGHT study. *Supportive Care in Cancer*. https://doi.org/10.1089/lrb.2021.0036
Related Research
The American journal of pathology
An Integrated Machine Learning and Genomic Framework for Precise Detection of Gastric Cancer
3 Aug 2026
Current opinion in chemical biology
Prediction of protein-protein interactions and co-complex models with deep learning
3 Aug 2026
European journal of radiology
A CT-based deep learning model to differentiate between benign and malignant adrenal lesions
3 Aug 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service